The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of genomic aberrations and additional therapies on survival outcomes of patients with operable non-small cell lung cancer (NSCLC) from the NEOSTAR study.
 
Nicolas Zhou
No Relationships to Disclose
 
Boris Sepesi
Consulting or Advisory Role - Bristol Myers Squibb Foundation
 
Cheuk Hong Leung
No Relationships to Disclose
 
Heather Y. Lin
No Relationships to Disclose
 
William Nassib William
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Merck; Pfizer; Roche
Speakers' Bureau - Boehringer Ingelheim
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); OSI Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck; Roche/Genentech
 
Annikka Weissferdt
No Relationships to Disclose
 
Apar Pataer
No Relationships to Disclose
 
Myrna Godoy
Consulting or Advisory Role - Siemens Healthineers
 
Frank V. Fossella
No Relationships to Disclose
 
George Blumenschein
No Relationships to Disclose
 
Xiuning Le
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Lilly; EMD Serono; Lilly; Spectrum Pharmaceuticals
Research Funding - Boehringer Ingelheim (Inst); Lilly (Inst)
 
Anne S. Tsao
Consulting or Advisory Role - ARIAD; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Epizyme; Genentech/Roche; HERON; Imedex; Lilly; MedImmune; Novartis; Takeda
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; MedImmune; Merck; Millennium; Polaris; Seagen; Seagen; Takeda
Patents, Royalties, Other Intellectual Property - UptoDate
 
Jianjun Zhang
Honoraria - CancerNet; Geneplus; Geneplus; Innovent Biologics; innovent biologics; Origimed; Roche; Sino-USA Biomedical Platform; Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Capital Medical University; Geneplus; Johnson & Johnson/Janssen
Research Funding - Merck
Travel, Accommodations, Expenses - innovent biologics; Zhejiang Cancer Hospital
 
Wayne L. Hofstetter
No Relationships to Disclose
 
Stephen Swisher
Travel, Accommodations, Expenses - Peter MacCallum Cancer Center
(OPTIONAL) Uncompensated Relationships - Ethicon
 
Ara A. Vaporciyan
No Relationships to Disclose
 
J. Jack Lee
Honoraria - AstraZeneca
 
Don Lynn Gibbons
Stock and Other Ownership Interests - Exact Sciences; Nektar
Consulting or Advisory Role - GlaxoSmithKline; Janssen Research & Development; Lilly; Menarini; Mitobridge; Ribon Therapeutics; Sanofi
Research Funding - AstraZeneca; Boehringer Ingelheim (Inst); Janssen Research & Development; Mirati Therapeutics (Inst); Mitobridge; Ribon Therapeutics; Takeda
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; BerGenBio; Takeda
 
John Heymach
Stock and Other Ownership Interests - Bio-Tree; Cardinal Spine
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; GlaxoSmithKline; Guardant Health; Hengrui Pharmaceutical; Lilly; Sanofi/Aventis; Spectrum Pharmaceuticals; Syntha Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Bayer; GlaxoSmithKline; Spectrum Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations
 
Tina Cascone
No Relationships to Disclose